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ABSTRACT
Twenty-five years ago a ‘‘new’’ protein was identified from cancers that caused hypercalcemia. It was credited for its ability to mimic
parathyroid hormone (PTH), and hence was termed parathyroid hormone-related protein (PTHrP). Today it is recognized for its
widespread distribution, its endocrine, paracrine, and intracrine modes of action driving numerous physiologic and pathologic
conditions, and its central role in organogenesis. The multiple biological activities within a complex molecule with paracrine modulation
of adjacent target cells present boundless possibilities. The protein structure of PTHrP has been traced, dissected, and deleted
comprehensively and conditionally, yet numerous questions lurk in its past that will carry into the future. Issues of the variable segments
of the protein, including the enigmatic nuclear localization sequence, are only recently being clarified. Aspects of PTHrP production and
action in the menacing condition of cancer are emerging as dichotomies that may represent intended temporal actions of PTHrP.
Relative to PTH, the hormone regulating calcium homeostasis, PTHrP ‘‘controls the show’’ locally at the PTH/PTHrP receptor throughout
the body. Great strides have been made in our understanding of PTHrP actions, yet years of exciting investigation and discovery are
imminent.  2012 American Society for Bone and Mineral Research.
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Historical Perspective
Parathyroid hormone-related protein (PTHrP) seemed toalmost come out of nowhere, produced by certain cancers,
mimicking parathyroid hormone (PTH) action, and causing the
complication of hypercalcemia. Fuller Albright, in 1941,(1) when
discussing a patient with renal carcinoma, a solitary metastasis,
and hypercalcemia, suggested that some tumors might cause
hypercalcemia by secreting PTH or something very like it. As with
many of his predictions he was ultimately proved correct, but not
before the passing of a few decades during which the concept of
‘‘ectopic PTH production’’ by cancers was promulgated as the
cause of nonmetastatic hypercalcemia.(2,3) Doubts began to
appear in the 1970s, when improved radioimmunoassays for PTH
indicated that the immunoreactivity in tumor or plasma of
patients with cancer differed from authentic PTH,(4–7) and with
some assays PTH immunoreactivity could not be detected at
all.(8) From this background three excellent clinical studies put
beyond reasonable doubt the biochemical similarity between
primary hyperparathyroidism and this syndrome of humoral
hypercalcemia of malignancy.(9–11) By that time, rapid, sensitive,
robust biological assays of PTH had been developed, and
extracts and culture supernatants of hypercalcemic animal and
human tumors were found to contain PTH-like adenylate cyclase
responses in osteoblast and kidney targets.(12–14) This paved the
way for purification of PTHrP from a human lung cancer cell
line,(15) a breast cancer cell line,(16) and a renal cancer cell line.(17)
The cloning of its cDNA(18,19) showed that eight of the first 13
residues of PTHrP were identical to those in PTH, any remaining
identities no more than expected by chance, and the structural
requirements for full biological activity of PTHrP contained
within the first 34 amino acids, as was known to be the case with
PTH.(20) These findings explained the biochemical similarities
between syndromes of PTH excess and nonmetastatic hypercal-
cemia in cancer, signaling the discovery of an evolutionary
relationship between these two molecules, most likely derived
from a common ancestor and evolving from a gene duplication
event. The PTHrP gene had amore complex structure than that of
PTH, but with similar intron–exon boundaries, and the marked
conservation of the PTHrP amino acid sequence in human, rat,
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mouse, chicken, and canine up to position 111 indicated that
important functions are likely to reside in this region. This was
the beginning of the rise of PTHrP to a position of great interest;
yet in many circles it still plays a secondary role in the family of
parathyroid hormones.
Soon after its discovery, it became apparent that, far from
being simply an evolutionary relic that mimics PTH action in
nonmetastatic cancer, PTHrP had major roles in other aspects of
cancer, in development, and in normal physiological functions
in postnatal life. At the time the receptor was discovered, it
was evident that this receptor functioned to relay both PTH
and PTHrP biological activity,(21) yet knockout of this PTH/PTHrP
receptor (PPR) highlighted the importance of PTHrP.(22,23)
Indeed, PTHrP is the master regulator, with widespread paracrine
actions (Fig. 1) and, as illustrated, by the pharmacological use of
PTH as an anabolic agent in the treatment of osteoporosis
where PTH administration actually mimics PTHrP actions locally
in the bone microenvironment.(24) Still, many questions remain
unanswered. In this perspective piece we briefly consider aspects
of PTHrP function in development and disease and pose
outstanding questions that despite 25 years of inquiry still linger.
PTHrP—Evolutionary Insights
It has long been accepted that PTH and PTHrP arose from gene
duplication; PTH located on human chromosome 11, and PTHrP
on chromosome 12. If conservation across species is evidence of
gene importance, PTHrP prevails: fugu fish PTH has 44% identity
with human PTH, whereas fugu fish PTHrP bears 53% similarity
with human PTHrP.(25) At the amino acid level, chicken PTH
shares 88% similarity with human, and chicken PTHrP shares 91%
similarity with human.(26) The first 111 amino acids of PTHrP are
extraordinarily conserved among many species. Interestingly,
PTH appears to play a paracrine role in lower vertebrates but
evolved in higher vertebrates with a more restricted yet vital
endocrine role. In fish, PTH produced in the gills is responsible
for local calcium regulation; whereas via evolution to tetrapods,
the parathyroid gland assumed an endocrine role as calcium
requirements shifted from an aquatic to a terrestrial environ-
ment.(27) PTHrP, having a fairly simple gene structure in lower
vertebrates, acquired a more complex structure with added
exons and alternative promoters with progression to humans,
and in parallel picked up a stronger paracrine emphasis.(26,28)
PTHrP—More than an Endocrine Factor
A great surge of interest and research activity came with the
finding that PTHrP is normally produced in many tissues and acts
in those sites in a paracrine manner. There are only three
identified circumstances in which PTHrP species are present in
the circulation and act in an endocrine manner: (1) the humoral
hypercalcemic syndrome, in which PTHrP is produced by tumors
and circulates to the bone to stimulate bone resorption(29,30); (2)
lactation, in which PTHrP is made in the breast and reaches the
circulation(31); and (3) fetal life, where PTHrP regulates maternal-
to-fetal placental calcium transport.(32,33) There remains to the
present time no convincing evidence of biologically relevant
circulating PTHrP levels otherwise in normal humans. Hence, the
Fig. 1. PTHrP paracrine actions. PTHrP has numerous paracrine actions in physiologic homeostasis, including roles in keratinocytes/hair follicles,
cartilage, vascular smooth muscle, bone, mammary gland development, tooth eruption, pancreas, and others not depicted. In comparison, PTH has
relatively fewer direct physiologic targets via its endocrine mode of operation in bone and kidney.
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vast majority of PTHrP actions, unlike PTH, are paracrine in
nature.
There are three splice-variant isoforms of PTHrP rendering
PTHrP 1-139, 1-173, or 1-141 with transcriptional regulation from
three distinct promoters.(34) The multiple products of posttrans-
lational processing including glycosylation, the short half-life of
PTHrP mRNA, and the multiple biological activities contained
within PTHrP, equip it ideally to function as a paracrine effector
with a developmental focus.(35–38) Together with the obvious
susceptibility of PTHrP to posttranslational modification through
proteolysis(39) and the generation of several constituent
peptides, this increased complexity highlights the leading
role of PTHrP, yet leaves questions that remain unanswered
to this day: Why are there three PTHrP splice variants in humans
but not in other mammals? What is the extent of biologically
relevant PTHrP peptide fragments, and how do they function?
Biologically active PTHrP peptide fragments functioning indepen-
dent of the N-terminus raise the question—are there yet
unidentified receptors?
Skeletal Actions
The physiological importance of PTHrP in the skeleton was
evident, with deletion of PTHrP resulting in death in mice
immediately after birth from respiratory failure, attributed to
defective rib cage formation.(40) Here PTHrP stands out from PTH,
whose later gene deletion resulted in a comparatively mild
phenotype.(41) Multiple defects in skeletal development con-
firmed the importance of PTHrP in fetal bone development.(42)
Whereas haploinsufficient PTHrP (þ/) mice are phenotypically
normal at birth, by 3 months of age they have low bone mass,
with a marked decrease in trabecular thickness and connectivity
and an abnormally high number of adipocytes in the bone
marrow.(43) PTHrPþ/ mice have compromised recruitment of
bone marrow precursors and increased osteoblast apoptosis
compared to wild-type mice. Importantly, this phenotype
was recapitulated in transgenic mice with osteoblast-specific
knockout of PTHrP, thereby confirming the role of osteoblast-
derived PTHrP in the process of bone formation.(24) These mice
also demonstrated reduced osteoclast formation, likely due to
impaired ability of PTHrP-null osteoblasts to support osteoclast
formation. Confounding work in this area is the nature of
PTHrP, with its low-abundance mRNA and protein products that
have been difficult to identify by conventional immunohisto-
chemical approaches. Coincident expression of PTHrP mRNA
and protein was noted in both chondrocytes and osteoblasts
in endochondral bone formation in the mouse, and both also
in preosteoblasts and actively synthesizing osteoblasts in a
regenerating bone model in the rabbit.(44) On the other hand,
using a PTHrP-lacZ knock-in mouse, Chen and colleagues(45)
were not able to demonstrate osteoblast-derived PTHrP
production, suggesting osteoblast-derived PTHrP would not
drive local bone formation.
In the growth plate, chondrocyte maturation is tightly
regulated by a paracrine PTHrP/Indian hedgehog (Ihh) signaling
loop. PTHrP produced by the distal perichondrium interacts
with the PPR expressed in the proliferative and prehypertrophic
zones of the growth plate. These findings support a key role
of PTHrP in controlling the pace of growth plate development
via preventing premature differentiation of chondrocytes into
prehypertrophic and hypertrophic chondrocytes.(46) More re-
cently, findings have extended to articular joints where evidence
suggests PTHrP is produced in response to loading and functions
in a similar Ihh signaling loop to support articular cartilage
maintenance.(47)
The favored current concept is that PTH, the hormone,
regulates calcium homeostasis in development and maturity.
PTHrP, the local factor, on the other hand, directs growth plate
development by controlling chondrocyte proliferation and
differentiation, while of these two proteins postnatally, PTHrP
is the main factor generated locally in bone and acting through
the PPR in bone remodeling, without normally contributing to
the maintenance of serum calcium levels. These studies also
highlight emerging evidence and pose questions: Does anabolic
PTH essentially co-opt PTHrP physiologic actions? Might we regard
the use of PTH in skeletal anabolic therapy as an attempt to
reproduce the local action of PTHrP?
Placental Calcium Transport
A role for PTHrP action in the placenta is highlighted by its ability
to promote transplacental calcium transport in sheep,(32) with
PTHrP(67-86) and (38-94) the most active peptides,(48,49) and no
action of amino-terminal PTHrP. Studies in genetically manipu-
lated mice confirm that PTHrP controls placental calcium
transport to bring about mineralization of the fetal skeleton,(50)
with the main PTHrP source being the placenta.
Smooth Muscle Relaxation
A particularly instructive example of the paracrine actions of
PTHrP is found in the smooth muscle beds of the vasculature. It
had been known since the 1920s that injection of parathyroid
extract in animals results in dose-dependent increases in blood
flow through a range of vascular beds, and decreases in blood
pressure.(51–54) When PTHrP was discovered it became clear that
this was not the normal function of PTH but instead, a local
physiological role of PTHrP, produced in smooth muscle beds of
the stomach and intestine, uterus, urinary bladder, and arterial
vessels, acting in all those tissues as a muscle relaxant.(36,55,56)
PTHrP expressed in smooth muscle acts rapidly to relax the
vasculature(57) through an endothelium-independent mecha-
nism, and vasoconstrictors such as angiotensin II induced a rapid
rise in PTHrP production.(58) Thus increased PTHrP production
following vasoconstriction could provide a mechanism to limit or
reverse this effect through the relaxing action of PTHrP on
smooth muscle. The paracrine production and action of PTHrP in
local vascular beds comes into action as required physiologically.
On the other hand, when PTH is administered systemically, with
simultaneous activation in many sites, the response of general
vasodilatation and decline in blood pressure is not surprising. Yet
where does PTHrP stand in the hierarchy of paracrine vasoactive
peptides?
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Mammary Gland Development
Although the neonatal lethality of PTHrP/ mice initially
presented difficulty in identifying tissue specificity, rescue of
these mice was achieved by directing PTHrP production to
cartilage with use of the collagen II promoter, allowing study of
the effect of the PTHrP-null phenotype on several other
organs.(59) In the case of the breast, ‘‘rescued’’ PTHrP-null mice
show failure of early breast ductal development, providing
strong evidence of a further paracrine role for PTHrP in
promoting branching morphogenesis.(59) With such dramatic
expressions of PTHrP involvement in early breast development,
it is perhaps not surprising that PTHrP emerges as a factor
important in breast cancer biology, yet a recent study provides
evidence against a PTHrP role in postnatal breast develop-
ment.(60) The discovery of receptor activator of NF-kB ligand
(RANKL) production by primitive ductal cells, acting on RANK in
mammary stem cells to promote their expansion,(61) highlights
the need for further investigation of the role of PTHrP and RANKL
in the breast.
Teeth and Skin
Further evidence supporting a prominent role for PTHrP in
development came with the PTHrP type II collagen promoter
rescue. These mice lack tooth eruption, a cardinal sign of
defective osteoclastogenesis.(62) PTHrP is produced by cells of
the enamel organ during development(63) and receptors for
PTHrP exist in the bone surrounding the developing tooth, and
also in the dental follicle and in cementoblasts lining the tooth
root surface.(64–66) Philbrick and colleagues(62) used a cytokeratin,
K14-PTHrP transgene, to show that replacement of PTHrP in the
enamel epithelium restores tooth eruption. Because osteoclasts
do not express PPR receptors, this supported the developmental
role of PTHrP to drive osteoclasts necessary for clearing the path
for the erupting tooth through a paracrine/juxtacrine interaction.
Murine studies were validated with human analyses of loss of
function of the PPR, revealing ankylosed and distorted tooth
development.(67)
Yet another tissue/organ site of PTHrP paracrine actions was
identified in the hair follicle, with reciprocal expression of the PPR
in the dermal components. Overexpression of PTHrP led to
premature termination of anagen and entrance to catagen in the
hair cycle.(68) PTHrP expression was identified to be high in late
anagen and thought to participate in the hair cycle but not
necessarily be essential for hair cycle progression. Similarly,
studies of PTHrP expression in keratinocytes found temporal-
dependent production of PTHrP with a reduction as keratino-
cytes differentiate,(69,70) suggesting a regulatory loop similar to
that found in cartilage development.
Pancreas
In the pancreas, islet cells were found to produce PTHrP as well
as bear the PPR, and PTHrP provides a robust increase in
intracellular calcium in beta cells.(71) All four endocrine cell
types—alpha, beta, delta, and pancreatic polypeptide cells—
produce PTHrP.(72) Overexpression of PTHrP as well as PTHrP 1-36
administration increases beta cell proliferation via cell-cycle
specific activation.(73) PTHrP overexpression in beta cells results
in islet hyperplasia and insulin-mediated hypoglycemia associ-
ated with reduced apoptosis.(74) This effect was also shown via
exogenous administration of PTHrP 1-36, supporting a local
mediated action at the PPR. PTHrP also increases beta cell
production of insulin, suggesting its consideration in therapeutic
strategies to improve islet growth and function.
PTHrP in Other Locations
Beyond the organ-focused investigations discussed above,
PTHrP has been detected in nearly every tissue/organ in the
body. Early reports of PTHrP and PPR expression in the heart,
brain, skeletal muscle, bladder, lungs, bile ducts, immune system,
liver, uterus, and testes, as well as most endocrine organs
including the pituitary and thyroid gland C-cells,(36,75) leave
unanswered questions years later as to the tissue-specific
significance of PTHrP in health and disease. However, many of
the early studies in this area did not have PTHrP knockout mice
available as negative controls, and did not use in situ
hybridization to detect PTHrP mRNA. To this day, challenges
surrounding the specificity of PTHrP immunohistochemistry still
need to be overcome.
PTHrP—The Intracrine Factor
A most intriguing early finding was the discovery that PTHrP
attains a nuclear/nucleolar location through a specific transport
process, and is likely to exert some of its functions from that site.
Nucleolar localization of PTHrP through a defined sequence in
themid-region is associated with enhanced chondrocyte survival
following prolonged periods of serum starvation.(76,77) Expres-
sion of PTHrP is cell cycle–specific in smooth muscle cells(78) and
keratinocytes,(78,79) and its mRNA highest at the G1 phase, when
localized to the nucleolus,(80) with cyclin-dependent kinase
phosphorylation of T85 resulting in exclusion of PTHrP from the
nucleus.(81)
Within the PTHrP sequence there are nucleus (CcN) and
nucleolus localization motifs, with the former being similar to
that described for the archetypal CcN-containing protein, SV40
T-antigen.(82) The mechanism of nuclear import requires PTHrP
interaction with importinb and the binding protein GTP-Ran,(83–85)
whereas cyclin-dependent kinase phosphorylation of T85 results
in exclusion of PTHrP from the nucleus.(81) A nuclear targeting
sequence that inhibits apoptosis exists at PTHrP (87-107),(76,86–88)
and PTHrP (109-139) is involved in its nuclear export.(89) Evidence
supports direct binding of PTHrP to RNA through a distinct motif
in the nucleolar-targeting signal (NTS)(90) and further points to
PTHrP as likely to exert important functions from its nuclear site.
So far, PTHrP appears to be the only protein classed at least in
some circumstances as a hormone, which possesses a CcN motif
and displays differential cellular localization (nuclear/nucleolar
versus cytoplasmic). There must be some important purpose
behind the evolutionary conservation of this property, and
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prompts the question: What is the significance of nuclear entry of
PTHrP in the many tissues in which PTHrP is considered to play a
local role?
The impact of other biological activities exerted by domains
within PTHrP was exemplified in two studies in mice, in one
of which knock-in of PTHrP (1-84), lacking both the nuclear
localization sequence (NLS) and C-terminal region while
retaining the bioactive amino-terminal, resulted in multiple
abnormalities and early lethality in mice.(91) Homozygous
mice exhibited skeletal growth retardation and osteopenia
associated with reduced proliferation and increased apoptosis of
osteoblasts as well as early senescence with altered expression
patterns and subcellular distribution of proliferative- and
senescence-related genes in multiple tissues. A further knock-
in of PTHrP (1-66) excluding a significant part of the mid-region
resulted in an even more severe phenotype and highlighted
the role of PTHrP in stem cells as well as later lineage cell
commitment.(92) These genetic studies in mice show that many
of the actions of PTHrP are not mediated by the amino-terminal
region, and among the generalized abnormalities, absence of the
mid-region, NLS, and C-terminal region result in greatly impaired
commitment and survival of osteogenic and hematopoietic
precursors.
PTHrP and Cancer
The significance of PTHrP in cancer was not confined to the
humoral hypercalcemic syndrome. Breast cancer was one of the
original sources of PTHrP (16). Hypercalcemic breast cancer
patients with metastatic bone disease have elevated plasma
PTHrP levels,(30) and 60% of primary breast cancers and 90%
of bone metastases are positive for PTHrP by immunohis-
tochemistry.(93,94) From this arose the concept that PTHrP
production in the bone marrow by breast cancer cells promotes
bone resorption, thus favoring tumor establishment and
expansion. Extensive experimental evidence was produced in
support of this,(95,96) including prevention and treatment of
tumor growth by inhibiting bone resorption, using bispho-
sphonates or neutralizing monoclonal antibodies against
PTHrP.(95,97) All of this accorded with the ‘‘seed and soil’’
hypothesis developed by Stephen Paget,(98) which depicted
bone as the favorable soil for the ‘‘seed’’ of breast cancer. Amajor
contributor to this cooperation is tumor production of PTHrP,
together with the several other cancer-derived factors that
influence bone metastasis establishment, including prostaglan-
dins and cytokines(96) and factors favoring the homing and/or
adherence of cancer cells to bone.(99) Although this emphasizes
PTHrP involvement in breast cancer, increasing evidence
implicates it in prostate, lung, renal, colon, lymphoid, and other
cancers.(100–104)
The history and findings need to be considered when
evaluating the place of PTHrP in the pathogenesis of bone
metastasis formation and progression. What is the relative
importance of PTHrP compared to other tumor derived factors and
the type of cancer (eg, breast versus prostate and their different
bone phenotypes)? When a PTHrP-producing tumor metastasizes to
bone, how does this locally produced factor compare in its biologic
impact with other tumor-derived factors? Is there a very early role
for PTHrP as an endocrine/tumor-derived circulating factor in
conditioning the bonemicroenvironment; ie, a premetastatic niche?
Does PTHrP influence tumor cell dormancy?
Does PTHrP indeed have an entirely independent function,
perhaps early in cancer development, of contributing to a less
invasive phenotype of the cancer? That suggestion comes from
a long-term, prospective study of consecutive patients at a
single center; that tumors positive for PTHrP at surgery were
independently predictive of improved patient survival, with
reduced metastases at all sites, including bone.(105,106) Such a
mechanism is distinct from the bone resorbing action later in
disease, which can explain the association of PTHrP production
with bone metastases.(107–110) Highlighting the controversy, of
two independent studies of genetically induced breast cancer
in mice, one concluded that loss of PTHrP expression resulted in
poorer outcomes in breast cancer(111) and the other concluded
the opposite, that PTHrP promotes the initiation and progression
of primary tumors.(112)
With PTHrP directing an important role in early mammary
gland development,(59,67,113) it might not be surprising if it were
to play a part in early stages of cancer development—but is this
concept of PTHrP a credible one?—protective at one stage of
cancer yet deleterious at another? Indeed PTHrP has been shown
to havemultiple and opposing roles in other circumstances, such
as in its ability to both protect and promote apoptosis in
osteoblastic cells and pneumocytes.(114–116) A similar example of
a dual action is transforming growth factor b (TGFb), which acts
early as a tumor suppressor by inhibiting proliferation of
epithelial, endothelial, and hematopoietic cells. Refractoriness to
these effects develops later, and overexpression of TGFb leads
to a microenvironment conducive to tumor growth.(117–119)
Confirmation of a dual role for PTHrP requires further clinical and
basic study, with the critical question: What are the temporal
implications of PTHrP in tumorigenesis? Are there different and
contrasting early and later actions?
Summary
After 25 years, what does PTHrP really do?
Can we regard PTH use as a pharmacological agent that is simply
a surrogate for what PTHrP does physiologically? We can only
speculate about the nature of the PTHrP molecule that gains
access through a paracrine mechanism to its adjacent target
cells, and the likelihood of multiple biological activities within
the molecule presents complex possibilities. Assuming that
full-length PTHrP is secreted, is that the predominant form that
interacts with target cells locally, or does its susceptibility to
proteolytic breakdown yield shorter products, even in that local
environment? PTHrP was designated as ‘‘related’’ to PTH, but it is
certainly not a distant cousin. Although knowledge of PTH
actions far preceded our knowledge of PTHrP, over the past
25 years PTHrP has emerged as the key regulator of normal
physiology as well as pathophysiologic events. Whereas
PTH actions center on its role in calcium metabolism, the
multifactorial nature of PTHrP will continue to give years of
exciting investigation.
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